期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 141, 期 -, 页码 67-91出版社
ELSEVIER
DOI: 10.1016/j.addr.2018.09.002
关键词
Immunocytokine; Immunotherapy; Biopharmaceutical; Armed antibody; Antibody engineering; Targeted therapy; Combination therapy; Check-point inhibitor; Cytokine; Cancer
资金
- ETH Zurich
- Swiss National Science Foundation [310030B_163479/1]
- European Research Council (ERC) under the European Union [670603]
- Swiss Federal Commission for Technology and Innovation [17072.1]
- Stiftung zur Krebsbekampfung
Cytokines have long been used for therapeutic applications in cancer patients. Substantial side effects and unfavorable pharmacokinetics limit their application and may prevent dose escalation to therapeutically active regimens. Antibody-cytokine fusion proteins (often referred to as immunocytokines) may help localize immunomodulatory cytokine payloads to the tumor, thereby activating anticancer immune responses. A variety of formats (e.g., intact IgGs or antibody fragments), molecular targets (e.g., extracellular matrix components and cell membrane antigens) and cytokine payloads have been considered for the development of this novel class of biopharmaceuticals. This review presents the basic concepts on the design and engineering of immunocytokines, reviews their potential limitations, points out emerging opportunities and summarizes key features of preclinical and clinical-stage products. (C) 2018 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据